Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6624 plus FOLFIRI in second-line metastatic KRAS-mutant colorectal adenocarcinoma
2011-003754-61Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of simtuzumab in colorectal adenocarcinoma, metastatic colorectal adenocarcinoma (mCRC), sponsored by Gilead Sciences. Started Mar 2012; status: terminated.
02
Drugs
simtuzumab
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2011-003754-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003754-61.